Biopharma Sustainability Roundtable Conference 2021
Multi-day peer-to-peer discussion
State of Biopharma Sustainability – Challenges and opportunities
How are we doing? Globalance Bank sector analysis
Participant survey outcomes and insights
Global ESG Policy Outlook
Update on global hard and soft regulatory changes affecting biopharma
Panel: Roundtable and regulatory representatives tbd
Frameworks and Standards: The evolving landscape
Standards harmonization: Value Reporting Foundation (SASB/IIRC), IFPMA, IFRS
Panel: Roundtable and standard-setting organization representatives tbd
Sustainable Investor Relations
ESG disclosure strategy and functional collaboration
Panel: Roundtable case studies tbd
Access to Medicine: Impact is the new bottom line
Measuring and valuing patient and social impact
Panel: Roundtable case studies tbd
Biopharma Sustainability and Long-Term Planning
Connecting ESG with business strategy: Building on the CEO Investor Forum
Panel: Roundtable case studies tbd
Sustainable Product Stewardship
Collective downstream product stewardship and social impact
Panel: Roundtable case studies tbd
Net-Zero Biopharma
Business strategy and environmental targets: Is Net-Positive impact possible?
Panel: Roundtable case studies tbd
Sustainable Vaccines and Antibiotics
New business models for addressing novel viruses and anti-microbial resistance
Panel: ATMF and Roundtable representatives tbd
Governance for Sustainability
Board oversight and governance models for sustainability and accountability
Panel: Current and former Biopharma Board members tbd
Human Capital Management: Diversity, Equity, and Inclusion
Pandemic impact on clinical trials, access to medicine, and social justice
Panel: Roundtable case studies tbd
Real-World Data and AI
Responsible technology and AI ethics, privacy, and compliance
Panel: Roundtable case studies tbd